ABEO - ABEONA THERAPEUTICS INC.

5.14
-0.020   -0.389%

Share volume: 2,086,714
Last Updated: 03-10-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.17%

PREVIOUS CLOSE
CHG
CHG%
$5.16
-0.02
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
41%
Profitability 35%
Dept financing 30%
Liquidity 75%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
5.98%
1 Month
1.58%
3 Months
-6.88%
6 Months
-23.85%
1 Year
-5.86%
2 Year
-34.19%
Key data
Stock price
$5.14
P/E Ratio 
3.29
DAY RANGE
$5.10 - $5.32
EPS 
$1.78
52 WEEK RANGE
$3.93 - $7.54
52 WEEK CHANGE
-$8.05
MARKET CAP 
270.751 M
YIELD 
N/A
SHARES OUTSTANDING 
54.191 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-14-2025
BETA 
0.40
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,323,073
AVERAGE 30 VOLUME 
$1,067,543
Company detail
CEO: Vishwas Seshadri
Region: US
Website: abeonatherapeutics.com
Employees: 90
IPO year: 1980
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Abeona Therapeutics Inc. develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A.

Recent news